CA
NZ
UK
AU
IND
US
For the better part of two years, institutional investors have nursed a peculiar anxiety: that generative AI would render enterprise software redundant. The logic held a certain surface appeal. If large language models could automate routine tasks, why would organisations pay premium subscription fees …
When Wall Street's major research desks issue coordinated recommendations for competing trillion-dollar companies, it typically signals either deep structural conviction or dangerous consensus. In this case, the recommendation of Micron Technology, Broadcom (NASDAQ: AVGO), and Alphabet Inc. (NASDAQ: GOOGL) as essential 2026 positions suggests …
Warren Buffett has long been candid about his indifference to technology investing. " This posture reflected his core investment philosophy: back businesses with durable competitive advantages, predictable cash flows, and rational pricing. Technology stocks, by his assessment, rarely met these criteria.
Anthropic's decision to file for an initial public offering represents far more than a single company'sLiquidityevent. It marks the formal opening of an era in which artificial-intelligence champions transition from private, venture-backed entities into public corporations subject to quarterlyEarningscycles and institutional scrutiny. The filing …
On the face of it, this makes no sense. A small biotech presents cancer drug data at one of the most watched oncology conferences in the world, the numbers look encouraging, and the stock falls by nearly half. That is the puzzle sitting in …
Blue Origin's ambitions in satellite broadband received an unexpected jolt when a New Glenn rocket test resulted in a catastrophic launch pad failure. NASA Administrator Jared Isaacman warned that repairs could extend well into 2028, a timeline that carries profound implications for Amazon's Project …
Not every merger announcement is created equal. Some are defensive moves by companies running low onOptions. Others are genuine resets, moments where two organisations come together and the result is more interesting than either was on its own. The deal announced between Rallybio Corporation …
Shares of LIXTE Biotechnology Holdings (NASDAQ: LIXT) surged 15% on strong trading activity after the company unveiled plans to transform itself from a clinical-stage biotechnology company into a participant in the rapidly expanding AI infrastructure ecosystem.
For eighteen months, the prospect of a SpaceX and Tesla merger has cast an unsettling shadow over investor confidence, compressing the valuation multiple applied to Tesla equity. The rumour resurfaces periodically, each iteration triggering fresh selling pressure as shareholders worry about equity dilution and …
There are moments in biotech when the market's verdict arrives swiftly and without ambiguity. Tuesday was one such moment for Edgewise Therapeutics, a Boulder-based clinical-stage company quietly building a case for itself in the fiercely competitive muscular dystrophy space. An 18% single-session gain is …
Please wait processing your request...